EMS-CHEMIE HOLDING (SWX:EMSN) stock has shown slight movement recently, with the share price closing at CHF 558. Over the past month, the stock is down about 7%, which reflects continued market volatility for the materials sector. See our latest analysis for EMS-CHEMIE HOLDING. While EMS-CHEMIE HOLDING’s 1-year total shareholder return stands at -16.2% amid recent volatility, the stock’s modest declines this quarter suggest fading momentum as investor sentiment weighs current risks against...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.